Get the Stockscreener App
11.04
5.96%
-0.70
After Hours:
11.15
0.11
+1.00%
Benitec Biopharma Inc stock is traded at $11.04, with a volume of 98,433.
It is down -5.96% in the last 24 hours and down -26.10% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$11.74
Open:
$11.87
24h Volume:
98,433
Relative Volume:
0.93
Market Cap:
$289.81M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.0081
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
-13.62%
1M Performance:
-26.10%
6M Performance:
+7.18%
1Y Performance:
+14.40%
1-Day Range:
$11.03
$11.96
1-Week Range:
$11.03
$13.27
52-Week Range:
$7.05
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.04 | 335.48M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Is Benitec Biopharma Inc. a good long term investmentUnrivaled growth potential - jammulinksnews.com
What drives Benitec Biopharma Inc. stock priceMarket-crushing stock picks - PrintWeekIndia
What analysts say about Benitec Biopharma Inc. stockFree Stock Market Mentorship - Autocar Professional
(BNTC) Investment Report - news.stocktradersdaily.com
Benitec Biopharma Inc. Stock Analysis and ForecastOutstanding capital appreciation - jammulinksnews.com
Does Benitec Biopharma Inc. stock pay reliable dividendsFree Investment Community - Newser
Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of “Buy” by Analysts - Defense World
What analysts say about Benitec Biopharma Inc. stock outlookSmart High Yield Swing Trades - Newser
Why Benitec Biopharma Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - beatles.ru
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid trial progress - Investing.com Australia
What makes Benitec Biopharma Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
How Benitec Biopharma Inc. stock performs during market volatilityFree Stock Market Forecasting Tools - Newser
Citizens JMP Reaffirms Their Buy Rating on Benitec Biopharma (BNTC) - The Globe and Mail
Benitec BioPharma stock maintains Market Outperform rating at JMP By Investing.com - Investing.com Canada
Benitec completes first cohort in gene therapy trial, advances to next phase By Investing.com - Investing.com South Africa
When the Price of (BNTC) Talks, People Listen - news.stocktradersdaily.com
Benitec Biopharma Advances BB-301 Clinical Study - TipRanks
Benitec Biopharma Provides Operational Updates - GlobeNewswire
Benitec Biopharma Inc. Provides Operational Updates - MarketScreener
Benitec Biopharma (BNTC) Moves Forward with Clinical Study Enrollment | BNTC Stock News - GuruFocus
Benitec completes first cohort in gene therapy trial, advances to next phase - Investing.com
Benitec's BB-301 Gene Therapy Achieves Key Safety Milestone, Phase 1b/2a Trial Set to Expand - Stock Titan
Benitec Biopharma (NASDAQ:BNTC) Now Covered by Analysts at TD Cowen - Defense World
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 3000 Index - MarketScreener
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 3000 Growth Index - MarketScreener
Benitec Biopharma(BNTC) Plunges 8.10% on Earnings Concerns - AInvest
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Trading (BNTC) With Integrated Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Grows Stake in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable - Nasdaq
(BNTC) Trading Report - news.stocktradersdaily.com
Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Position Boosted by Ameriprise Financial Inc. - Defense World
Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Form 424B3 Benitec Biopharma Inc. - StreetInsider
Northern Trust Corp Grows Stock Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):